Coagulation and hemostasis testing evaluates the functional integrity of the blood clotting system and the interaction between blood and medical devices, covering key assays such as prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen. These tests are required for the hemocompatibility evaluation of blood-contacting devices under ISO 10993-4 and are equally indispensable for diagnosing bleeding disorders and monitoring anticoagulant therapy. This article explains the test principles, applicable standards, sample requirements, methods, and typical applications provided by accredited third-party laboratories.
Technical Overview
Hemostasis is the physiological process that prevents and stops bleeding through two coordinated mechanisms. Primary hemostasis involves platelet adhesion, activation, and aggregation, which form an initial platelet plug at the site of vascular injury. Secondary hemostasis, known as the coagulation cascade, stabilizes this plug through a sequence of enzymatic reactions that convert fibrinogen into an insoluble fibrin clot.
The classical coagulation cascade is divided into the intrinsic pathway (contact activation system, involving factors XII, XI, IX, and VIII), the extrinsic pathway (tissue factor pathway, involving factor VII), and the common pathway (factors X, V, II, and I), which converge to generate thrombin and ultimately fibrin. Coagulation and hemostasis testing measures the function of these pathways in vitro, typically by timing the formation of a fibrin clot in citrated plasma after adding specific triggering reagents.
For medical devices intended for blood contact, ISO 10993-4 (and its Chinese counterpart GB/T 16886.4) requires hemocompatibility evaluation across five categories: thrombosis, coagulation, platelets, hematology, and the complement system. Within this framework, coagulation assays such as PT, APTT, and TT are used to determine whether a device or material delays, accelerates, or otherwise alters clot formation compared with appropriate controls.
In the clinical context, the same assays are foundational laboratory tools for screening bleeding and thrombotic disorders, guiding the diagnosis of hemophilia, von Willebrand disease, disseminated intravascular coagulation, liver dysfunction, and vitamin K deficiency, and for monitoring warfarin therapy (PT/INR) and heparin therapy (APTT). Reference methods and pre-analytical requirements are established by CLSI guidelines such as H21, H47, and H58, together with WHO recommendations for PT/INR standardization.
Testing Samples
Blood-Contacting Medical Devices
Testing is performed on finished devices or device components that contact circulating blood, either directly or indirectly. Typical examples include:
- Intravascular catheters, guidewires, and introducer sheaths
- Vascular stents, stent grafts, and vascular grafts
- Heart valves, ventricular assist devices, and artificial heart components
- Extracorporeal circulation products such as oxygenators, tubing sets, and hemodialyzers
- Blood collection bags, transfusion and infusion sets, syringes, needles, and blood filters
- Cell separation and apheresis consumables
Materials, Coatings, and Extracts
For raw materials and surface-modified products, such as devices bearing heparin or other antithrombotic coatings, test articles may be evaluated as direct-contact samples or as extracts prepared according to ISO 10993-12. Extraction vehicles commonly include citrated platelet-poor plasma or citrated whole blood, with extraction ratios calculated from the sample surface area, mass, or device configuration.
Clinical and Research Specimens
When testing is performed for diagnostic or research purposes, specimens typically include citrated platelet-poor plasma, platelet-rich plasma, and whole blood collected from healthy volunteer donors or patient populations. Animal blood, including rabbit, ovine, or porcine blood, may be used where scientifically justified and consistent with the study protocol.
Testing Items
Core coagulation and hemostasis test items include the following:
- Prothrombin Time (PT) and INR: Assesses the extrinsic and common pathways; the International Normalized Ratio (INR) standardizes PT results for anticoagulant monitoring.
- Activated Partial Thromboplastin Time (APTT): Assesses the intrinsic and common pathways and is sensitive to heparin, lupus anticoagulants, and factor deficiencies.
- Partial Thromboplastin Time (PTT): A non-activated variant used in device hemocompatibility studies per ISO 10993-4.
- Thrombin Time (TT): Measures the conversion of fibrinogen to fibrin and is highly sensitive to heparin contamination and abnormal fibrinogen.
- Fibrinogen Concentration: Quantifies the level of functional fibrinogen, a key acute-phase reactant and clot precursor.
- Coagulation Factor Assays: Single-factor activity measurements, such as factor VIII or factor IX, for deficiency characterization.
- Platelet Count and Function: Includes platelet counting, aggregation studies, and activation markers to evaluate primary hemostasis.
- D-Dimer and Fibrin Degradation Products (FDP): Immunological markers of fibrinolysis and thrombotic activity.
- Thrombin Generation and Thrombin-Antithrombin (TAT) Complex: Global and molecular indicators of coagulation activation.
Under ISO 10993-4, coagulation testing is frequently combined with complementary hemocompatibility endpoints, such as platelet adhesion, hemolysis, leukocyte count, and complement activation, to provide a complete blood-device interaction profile.
Testing Methods
Clot-Based Coagulometric Assays
The most widely used approach measures the time to clot formation in citrated plasma after recalcification with pathway-specific reagents. Thromboplastin triggers the PT assay, a contact activator combined with phospholipid and calcium triggers the APTT assay, and exogenous thrombin triggers the TT assay. Clot formation is detected by optical densitometry or mechanical (magnetic or impedance) sensors, and results are reported in seconds and compared against pooled normal control plasma.
Chromogenic and Immunological Assays
Chromogenic assays use synthetic peptide substrates to quantify amidolytic enzyme activity, offering high precision where clot-based endpoints are affected by interference. Immunological methods, including ELISA and latex-enhanced agglutination, are applied to D-dimer, FDP, and TAT complex measurement, providing sensitive markers of fibrinolytic and coagulation activation.
Viscoelastic Whole-Blood Methods
Viscoelastic hemostatic assays evaluate clot initiation, kinetics, strength, and lysis in whole blood, providing a global picture of coagulation status. These methods are increasingly used in research settings and for evaluating the overall hemostatic impact of blood-contacting materials.
Sample Preparation and Study Design
For device testing, study design follows ISO 10993-12 and ISO 10993-4. Direct-contact designs incubate fresh, anticoagulated blood with the intact device or simulate physiologic flow conditions in dynamic loop models, while indirect designs test extracts. Blood is collected into 3.2 percent sodium citrate at a strict 9:1 blood-to-anticoagulant ratio, gently homogenized, and tested within validated time limits, generally within a few hours of collection. Each study includes negative and positive controls, replicate measurements, and statistical comparison against controls, with hemolysis and clot mass observations frequently recorded alongside coagulation times.
Applications
Coagulation and hemostasis testing supports a broad range of regulatory, clinical, and industrial applications:
- Hemocompatibility evaluation and biological evaluation reports for medical device registration submissions in major global markets
- Research and development screening of novel biomaterials and surface coatings intended to reduce thrombogenicity
- Quality control and batch verification of heparin-coated and antithrombotic-treated products
- Clinical laboratory screening for bleeding disorders, thrombophilia, and coagulopathy
- Monitoring of oral anticoagulant and heparin therapy in patient management
- Pharmaceutical development and preclinical evaluation of anticoagulant and procoagulant drug candidates
- Academic research on thrombosis mechanisms, blood-material interactions, and transfusion medicine
FAQ
What is the difference between PT and APTT?
PT evaluates the extrinsic (tissue factor) and common pathways and is the primary test for monitoring warfarin therapy through the INR. APTT evaluates the intrinsic (contact) and common pathways and is the primary test for monitoring unfractionated heparin and screening for hemophilia and lupus anticoagulants. Together they provide complementary coverage of the coagulation cascade.
Which standard governs coagulation testing for blood-contacting medical devices?
ISO 10993-4, Biological evaluation of medical devices, Part 4: Selection of tests for interactions with blood, is the primary standard. In China, the equivalent standard is GB/T 16886.4. Sample preparation follows ISO 10993-12, and pre-analytical and analytical procedures are supported by CLSI harmonized guidelines.
What type of blood specimen is used?
Whole blood anticoagulated with 3.2 percent sodium citrate is the standard specimen. Platelet-poor plasma is prepared by centrifugation for clot-based assays, while whole blood is used for viscoelastic assays and direct-contact device studies. Strict control of the blood-to-citrate ratio, mixing, and testing time is essential for valid results.
How is the choice made between direct-contact and extract methods?
The choice depends on the intended use of the device. Devices with direct, dynamic blood exposure, such as catheters, oxygenators, and dialyzers, are typically evaluated by direct-contact or flow-loop methods. Materials with limited or indirect blood contact may be evaluated through extracts prepared in citrated plasma or blood according to ISO 10993-12.
How are prolonged APTT or TT results interpreted in device testing?
A statistically significant prolongation of APTT or TT relative to controls indicates that the device or material inhibits coagulation, which may reflect leachable substances, heparin-like activity, or surface-mediated factor adsorption. Results are interpreted together with platelet, hematology, hemolysis, and complement endpoints as part of the overall ISO 10993-4 risk assessment.
Can animal blood be used instead of human blood?
Human blood is generally preferred because it best represents clinical exposure. Animal blood, such as rabbit, ovine, or porcine blood, may be used where scientifically justified, such as in screening studies, provided species differences in coagulation biology are acknowledged and the rationale is documented in the test protocol.
